Press & news
Biofidelity announces the commercial launch of ASPYRE®-Lung in the US
Sep 5. 2023
Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.
Biofidelity Introduces ASPYRE®-Lung at ASCO 2023
May 25. 2023
ASPYRE simplifies and accelerates the detection of actionable biomarkers in both DNA and RNA from either tissue or plasma within two days.
Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director
Nov 17. 2022
Biofidelity has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director.
Business Weekly Awards 2023
Sep 28. 2023
Barnaby Balmforth, CEO of Biofidelity receives the Life Science Innovation Award from AstraZeneca’s Shaun Grady and Sir Greg Winter.
Biofidelity Introduces Novel Lung Cancer Assay for Precision Medicine
Sep 7. 2023
Biofidelity, a British genomic technology company with U.S. headquarters in Morrisville, has commercially launched a novel assay to guide the treatment of non-small cell lung cancer in U.S. patients. The assay, called ASPYRE-Lung, simplifies and accelerates the detection of biomarkers for lung cancer, enabling clinicians to determine which treatment is best for each patient at a lower cost than current RNA and DNA sequencing tests, and in days instead of weeks, the company said in a news release.
Winning the race to fight lung cancer? Medtech company with RTP lab says it can speed up biomarker test at lower costs
Sep 7. 2023
Lung cancer is the leading cause of cancer deaths in the US, with more than 200,000 cases diagnosed every year, according to a Biofidelity press release from Tuesday. And while targeted treatments can offer big benefits to lung cancer patients, the company says that 65% of lung cancer patients start treatment without them.